[logo]
www.cbioinc.com Press Release
- -----------------
- -------------------------------------------------------------------------------
FOR IMMEDIATE RELEASE: CONTACT:
Chris Peng Mao, CEO
86-10-8525-1616
info@cbioinc.com
Brian Rafferty
212-889-4350
brian.rafferty@taylor-rafferty.com
China Biopharmaceuticals Retains WR Hambrecht + Co as Strategic Advisor
BEIJING, China, September 5, 2006 -- China Biopharmaceuticals Holdings, Inc.
(OTC BB: CHBP), a leading Chinese pharmaceutical company focused on the
development, manufacturing and distribution of innovative drugs in China, today
announced that it has engaged W.R. Hambrecht + Co., LLC ("WR Hambrecht + Co") as
exclusive financial advisor.
Chris Mao, CHBP CEO stated, "It is clear to our management team that WR
Hambrecht + Co is the right partner to help us build our financial capabilities
and help us achieve our short- and long-term corporate goals. This agreement
reflects our ongoing strategic progress and demonstrates our commitment to
building shareholder value."
Stephen Globus, a CHBP Director commented, "On behalf of our board members from
China, Hong Kong and New York, I would like to welcome WR Hambrecht + Co to the
China Biopharmaceuticals team. They are a world-class partner with unique
strengths in the China market and the healthcare sector. We look forward to
working together with WR Hambrecht + Co as we build CHBP into a premier Chinese
pharmaceutical company."
About China Biopharmaceuticals Holdings China Biopharmaceutical Holdings, Inc
(CHBP) is a research driven pharmaceutical company dedicated to the discovery,
development, manufacturing and marketing of small and large molecule
pharmaceutical products, including medicines, vaccines, and active
pharmaceutical ingredients for various categories of diseases. CHBP is a US
public company with operating subsidiaries and senior management based in China.
For further information, please visit our website at www.cbioinc.com.
About WR Hambrecht + Co
WR Hambrecht + Co (www.wrhambrecht.com) provides underwriting and advisory
services for healthcare, technology and emerging growth companies, as well as
equity research, sales and trading, full-service and online brokerage and
private equity offerings for institutions and individuals. WR Hambrecht + Co is
headquartered in San Francisco with offices in Boston, Chicago, London,
Montreal, New York, Philadelphia and Stamford, CT.
Safe Harbor Statement
The statements contained herein that are not historical facts are "forward
looking statements" within the meaning of Section 21E of the Securities and
Exchange Act of 1934, as amended, and the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements may be identified by, among other
things, the use of forward-looking terminology such as "believes," "expects,"
"may," "will," "should," or "anticipates" or the negative thereof or other
variations thereon or comparable terminology, or by discussions of strategy that
involve risks and uncertainties. In particular, our statements regarding the
potential growth of the markets are examples of such forward-looking statements.
The forward-looking statements include risks and uncertainties, including but
not limited to, general economic conditions and regulatory developments, not
within our control. The factors discussed herein and expressed from time to time
in our filings with the Securities and Exchange Commission could cause actual
results and developments to be materially different from those expressed or
implied by such statements. The forward looking statements are made only as of
the date of this filing, and we undertake no obligation to publicly update such
forward-looking statements to reflect subsequent events or circumstances.
###